Akiram Therapeutics and ITM Sign Lutetium-177 Supply Agreement to Support Development of AKIR001 for the Treatment of Solid Tumors

PartnershipAKIR001Positive

AI Analysis

Summary

Akiram Therapeutics and ITM Isotope Technologies Munich have signed a supply agreement for non-carrier-added Lutetium-177 to support the development of AKIR001 for solid tumors. This partnership enables continued clinical development of Akiram's molecular radiotherapy candidate.

Outcome Details

Supply agreement for non-carrier-added Lutetium-177 to support development

Importance:5/10

Sentiment:

0.30

molecular radiotherapyradiopharmaceuticallutetium-177partnershipsupply agreement

Related Companies

$MOLN $SOBI.ST $SLDB

Read the original article

Published by PR Newswire Pharma on August 20, 2026 6:22 AM

Read Original